Skip to Main Content

Author Details

James M Ford
Stanford University
1989
238
76
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36662819National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).Clin Cancer Res2023
37589839Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.Breast Cancer Res Treat2023
37531248The New NCI Precision Medicine Trials.Clin Cancer Res2023
37057674Clinical implications of conflicting variant interpretations in the cancer genetics clinic.Genet Med2023
36787506Therapeutic Implications of Oncogenic Missense <i>HER2</i> (<i>ERBB2</i>) Mutations in Gastric Adenocarcinoma.JCO Precis Oncol2023
36746967Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.Nat Commun2023
35138919Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.JCO Precis Oncol2022
35587343A Novel Framework for the Next Generation of Precision Oncology Targets.JAMA Oncol2022
35771165The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric Cancer.Cancer Epidemiol Biomarkers Prev2022
35830623Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1.ACS Chem Biol2022
35726067Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer.Nat Genet2022
35681696Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.Cancers (Basel)2022
36215283Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.PLoS One2022
36228963Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.Ann Oncol2022
36053203Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.J Natl Cancer Inst2022
36117009Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.Gynecol Oncol2022
36253484A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.Nat Cancer2022
35158993Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes.Cancers (Basel)2022
35286930Somatic tumor testing implications for Lynch syndrome germline genetic testing.Cancer Genet2022
32339239One Step Further Toward Defining the Exceptional Cancer Responder.J Natl Cancer Inst2021
34941969Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.PLoS One2021
34416278Subtle endoscopic manifestations of diffuse signet cell gastric adenocarcinoma in patients with CDH1 mutations.Gastrointest Endosc2021
33369189Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.Cancer Med2021
33276309A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma.DNA Repair (Amst)2021
33320347Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.Cancer2021
32193467Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer.Sci Rep2020
31895607Statistical Methods in Precision Oncology.J Clin Oncol2020
32068069Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.J Mol Diagn2020
31796517Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.Clin Cancer Res2020
33225206Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford.JNCI Cancer Spectr2020
33447520Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.J Clin Transl Hepatol2020
32758476Hereditary diffuse gastric cancer: updated clinical practice guidelines.Lancet Oncol2020
32954205Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers.JCO Precis Oncol2020
31278053HAT1 Coordinates Histone Production and Acetylation via H4 Promoter Binding.Mol Cell2019
34322651Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk.JCO Precis Oncol2019
32259017Germline Testing for Patients With <i>BRCA1/2</i> Mutations on Somatic Tumor Testing.JNCI Cancer Spectr2019
31439813Genomics in medicine: a novel elective rotation for internal medicine residents.Postgrad Med J2019
31182087Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.BMC Med Genomics2019
31433991Chromatin Remodeling in Response to BRCA2-Crisis.Cell Rep2019
31175093High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.Clin Cancer Res2019
31311767Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue.DNA Repair (Amst)2019
28640241Long-read genome sequencing identifies causal structural variation in a Mendelian disease.Genet Med2018
35135157Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?JCO Precis Oncol2018
35135146Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies.JCO Precis Oncol2018
35135120Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study.JCO Precis Oncol2018
30099370NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.J Natl Compr Canc Netw2018
29937436Screening for founder and recurrent BRCA mutations in Hong Kong and US Chinese populations.Hong Kong Med J2018
30224110From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.Value Health2018
30087100Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst.Cold Spring Harb Mol Case Stud2018
29581131Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.Clin Cancer Res2018
  • 1 - 50 of 238

Recommended Authors

Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 21
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 2
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 4
Zhuo Chen
The First Hospital of Lanzhou University
Career Start Year 2002
Number of shared co-authors 2
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 2
Teresa Ram??n y Cajal
Familial Cancer Clinic, Hospital Sant Pau
Career Start Year 2000
Number of shared co-authors 12
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 4
Eddy S Yang
University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 4
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 1
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 8
Dirce Maria Carraro
AC Camargo Cancer Center
Career Start Year 1998
Number of shared co-authors 5
Shiaw-Yih Lin
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 3
Mar??a J Garc??a
Spanish National Cancer Research Centre (CNIO)
Career Start Year 1996
Number of shared co-authors 12
Marbin Pineda
Center for Cancer Research, National Cancer Institute
Career Start Year 1995
Number of shared co-authors 14
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 17
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 6
Simon N Powell
Memorial Sloan Kettering Cancer Center
Career Start Year 1990
Number of shared co-authors 4
Katherine Stemke-Hale
MD Anderson Cancer Center, University of Texas
Career Start Year 1989
Number of shared co-authors 5
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 17
Barbara L Weber
Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania
Career Start Year 1988
Number of shared co-authors 16
Eivind Hovig
Center for Bioinformatics, University of Oslo
Career Start Year 1987
Number of shared co-authors 7
Alvaro N A Monteiro
H. Lee Moffitt Cancer Center & Research Institute
Career Start Year 1985
Number of shared co-authors 16
Laura J Van't Veer
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 26
Olli Kallioniemi
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 6
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 3
Stephen H Friend
University of Oxford
Career Start Year 1978
Number of shared co-authors 12
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 8
Anne-Lise B??rresen-Dale
Institute for Cancer Research, Oslo University Hospital
Career Start Year 1972
Number of shared co-authors 15
Paolo Radice
Ospedale Circolo e Fondazione Macchi
Career Start Year 1969
Number of shared co-authors 20
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Career Start Year 1959
Number of shared co-authors 28

Collaborators

Uri Ladabaum
Stanford University School of Medicine
Co-authored papers 13
Teri A Longacre
Co-authored papers 13
Judy E Garber
Dana-Farber Cancer Institute
Co-authored papers 12
David G Huntsman
University of British Columbia
Co-authored papers 8
Karyn A Goodman
Mount Sinai Hospital
Co-authored papers 8
Susan M Domchek
Co-authored papers 7
Brendan C Visser
Co-authored papers 6
Pardeep Kaurah
University of British Columbia
Co-authored papers 6
Jason Klapman
Co-authored papers 5
Dayna S Early
Co-authored papers 5
Michael Snyder
Stanford University
Co-authored papers 5
Kasmintan A Schrader
University of British Columbia
Co-authored papers 4
Janine Senz
University of British Columbia
Co-authored papers 4
Alice S Whittemore
Co-authored papers 3
Ronald W Davis
Stanford University
Co-authored papers 3
William M Grady
. Fred Hutchinson Cancer Center
Co-authored papers 3
Steven Gallinger
Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto
Co-authored papers 3
Matthew T Wheeler
Stanford University School of Medicine
Co-authored papers 3
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 3
Fergus J Couch
Mayo Clinic
Co-authored papers 3
Manish A Shah
Weill Cornell University
Co-authored papers 3
Carla Oliveira
Co-authored papers 3
Stephen E Lincoln
Co-authored papers 3
Eric T Kool
Co-authored papers 3
Christina Curtis
Stanford University School of Medicine
Co-authored papers 3
Anne-Marie Martin
Novartis Pharmaceuticals
Co-authored papers 3
Andrea L Richardson
Co-authored papers 3
Katherine L Nathanson
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Co-authored papers 3
Christopher C Benz
Buck Institute for Research on Aging
Co-authored papers 3
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 2
Release 1.2